Literature DB >> 2724432

Topical oxybutynin chloride for relaxation of dysfunctional bladders.

C B Brendler1, L C Radebaugh, J L Mohler.   

Abstract

Eleven patients with persistent urge incontinence and frequent side effects on oral anticholinergic agents were treated with oxybutynin chloride administered intravesically. Five mg. tablets were dissolved in saline, and the solution was instilled twice daily and retained for 30 minutes. One patient was unable to retain the medication because of severe detrusor hyperreflexia and was eliminated from the study. The remaining 10 patients all reported subjective improvement following treatment and all became totally continent. No side effects were observed. In these 10 patients mean bladder capacity increased from 224 to 360 ml. (p less than 0.01) and mean maximum filling pressure decreased from 33 to 24 cm. water (p equals 0.17). Two additional patients with continent ileocecal urinary diversions were treated with topical oxybutynin chloride instilled directly into the intestinal reservoir. Both patients reported improved comfort with filling and 1 demonstrated a decrease in uninhibited contractions. These encouraging results suggest that treatment with topical oxybutynin chloride is an effective alternative in patients with voiding dysfunction who either are unresponsive to or have intolerable side effects on oral medications.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2724432     DOI: 10.1016/s0022-5347(17)41304-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

Review 1.  [Treatment of urinary incontinence].

Authors:  M Juarranz Sanz; R Terrón Barbosa; M Roca Guardiola; T Soriano Llora; M Villamor Borrego; M J Calvo Alcántara
Journal:  Aten Primaria       Date:  2002-09-30       Impact factor: 1.137

Review 2.  [Intravesical treatment of overactive bladder syndrome].

Authors:  A Haferkamp; M Hohenfellner
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

Review 3.  Update on overactive bladder: pharmacologic approaches on the horizon.

Authors:  Eric S Rovner; Alan J Wein
Journal:  Curr Urol Rep       Date:  2003-10       Impact factor: 3.092

4.  Intravesical oxybutinin chloride in children with intermittent catheterization: sonographic findings.

Authors:  J M Zerin; M A DiPietro; M L Ritchey; D A Bloom
Journal:  Pediatr Radiol       Date:  1994

5.  A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder.

Authors:  Michael J Kennelly
Journal:  Rev Urol       Date:  2010

6.  Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial.

Authors:  Jan Krhut; Peter Zvara
Journal:  Int Urol Nephrol       Date:  2010-06-20       Impact factor: 2.370

Review 7.  Intravesical oxybutynin in the pediatric neurogenic bladder.

Authors:  John Lazarus
Journal:  Nat Rev Urol       Date:  2009-11-10       Impact factor: 14.432

Review 8.  [Overactive bladder--treatment with antimuscarinic agents].

Authors:  K Höfner
Journal:  Urologe A       Date:  2003-05-20       Impact factor: 0.639

9.  The evolution of transdermal therapy for overactive bladder.

Authors:  Peter K Sand
Journal:  Curr Urol Rep       Date:  2009-09       Impact factor: 3.092

Review 10.  Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

Authors:  Y E Yarker; K L Goa; A Fitton
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.